share_log

Earnings Preview For BioLine Rx

Earnings Preview For BioLine Rx

BioLine rx業績預覽
Benzinga ·  11/22 22:03

BioLine Rx (NASDAQ:BLRX) is preparing to release its quarterly earnings on Monday, 2024-11-25. Here's a brief overview of what investors should keep in mind before the announcement.

bioline rx (納斯達克:BLRX) 正在準備於2024年11月25日發佈其季度業績。在公告之前,這裏有一些投資者需要注意的要點。

Analysts expect BioLine Rx to report an earnings per share (EPS) of $-0.10.

分析師預計bioline rx的每股收益爲$-0.10。

Anticipation surrounds BioLine Rx's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.

投資者們期待bioline rx的公告,希望聽到超過預期的業績以及對下個季度的積極指引。

New investors should understand that while earnings performance is important, market reactions are often driven by guidance.

新投資者應該了解,儘管收益表現很重要,但市場反應往往受到指引的推動。

Overview of Past Earnings

過去收益的概述

During the last quarter, the company reported an EPS beat by $0.14, leading to a 8.88% increase in the share price on the subsequent day.

在上一個季度,該公司報告的每股收益超過預期0.14美元,這導致次日股價上漲了8.88%。

Here's a look at BioLine Rx's past performance and the resulting price change:

以下是bioline rx的過去表現及其所帶來的價格變化:

Quarter Q2 2024 Q1 2024 Q4 2023 Q3 2023
EPS Estimate -0.14 -0.29 -0.22 -0.21
EPS Actual 0 -0.01 -0.15 -0.26
Price Change % 9.0% -4.0% 8.0% -11.0%
季度 2024年第二季度 2024年第一季度 Q4 2023 Q3 2023
每股收益預估值 -0.14 -0.29 -0.22 -0.21
每股收益實際值 0 -0.01 -0.15 -0.26
價格變更% 9.0% -4.0% 8.0% -11.0%
bigjpg

BioLine Rx Share Price Analysis

bioline rx 股價分析

Shares of BioLine Rx were trading at $0.32325 as of November 21. Over the last 52-week period, shares are down 77.86%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.

截至11月21日,bioline rx的股價爲0.32325美元。在過去52周內,股價下跌了77.86%。鑑於這些回報通常是負面的,長期股東在這次業績發佈前可能有些不滿。

To track all earnings releases for BioLine Rx visit their earnings calendar on our site.

要查看bioline rx的所有業績發佈,請訪問我們網站上的業績日曆。

This article was generated by Benzinga's automated content engine and reviewed by an editor.

本文是由Benzinga的自動內容引擎生成,並由編輯審核。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論